These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 33718109)

  • 1. EZH2-miRNA Positive Feedback Promotes Tumor Growth in Ovarian Cancer.
    Liu T; Cai J; Cai J; Wang Z; Cai L
    Front Oncol; 2020; 10():608393. PubMed ID: 33718109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion.
    Yi X; Guo J; Guo J; Sun S; Yang P; Wang J; Li Y; Xie L; Cai J; Wang Z
    Sci Rep; 2017 Jun; 7(1):3568. PubMed ID: 28620234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of EZH2 in Epithelial Ovarian Cancer: From Biological Insights to Therapeutic Target.
    Li H; Zhang R
    Front Oncol; 2013; 3():47. PubMed ID: 23494175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells.
    Cardenas H; Zhao J; Vieth E; Nephew KP; Matei D
    Oncotarget; 2016 Dec; 7(51):84453-84467. PubMed ID: 27563817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EZH2-mediated repression of GSK-3β and TP53 promotes Wnt/β-catenin signaling-dependent cell expansion in cervical carcinoma.
    Chen Q; Zheng PS; Yang WT
    Oncotarget; 2016 Jun; 7(24):36115-36129. PubMed ID: 27092879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP27B1 Downregulation: A New Molecular Mechanism Regulating EZH2 in Ovarian Cancer Tumorigenicity.
    Huo X; Sun H; Qian Q; Ma X; Peng P; Yu M; Zhang Y; Yang J; Cao D; Gui T; Shen K
    Front Cell Dev Biol; 2020; 8():561804. PubMed ID: 33163485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells.
    Koumangoye RB; Andl T; Taubenslag KJ; Zilberman ST; Taylor CJ; Loomans HA; Andl CD
    Mol Cancer; 2015 Feb; 14():24. PubMed ID: 25644061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-212/132 is epigenetically downregulated by SOX4/EZH2-H3K27me3 feedback loop in ovarian cancer cells.
    Lin L; Wang Z; Jin H; Shi H; Lu Z; Qi Z
    Tumour Biol; 2016 Nov; ():. PubMed ID: 27812929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
    Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
    J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
    Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
    Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysregulation of histone H3 lysine 27 trimethylation in transforming growth factor-β1-induced gene expression in mesangial cells and diabetic kidney.
    Jia Y; Reddy MA; Das S; Oh HJ; Abdollahi M; Yuan H; Zhang E; Lanting L; Wang M; Natarajan R
    J Biol Chem; 2019 Aug; 294(34):12695-12707. PubMed ID: 31266808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of tumorigenicity by microRNA-138 through inhibition of EZH2-CDK4/6-pRb-E2F1 signal loop in glioblastoma multiforme.
    Qiu S; Huang D; Yin D; Li F; Li X; Kung HF; Peng Y
    Biochim Biophys Acta; 2013 Oct; 1832(10):1697-707. PubMed ID: 23707559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of sonication on results of ChIP-seq experiments involving PRC2 related proteins].
    Yang G; Jiao F; Lü R; Guo R
    Sheng Wu Gong Cheng Xue Bao; 2020 Feb; 36(2):341-352. PubMed ID: 32148006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia.
    Chen J; Li J; Han Q; Sun Z; Wang J; Wang S; Zhao RC
    Exp Biol Med (Maywood); 2012 Sep; 237(9):1110-6. PubMed ID: 22956625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic maintenance of stemness and malignancy in peripheral neuroectodermal tumors by EZH2.
    Burdach S; Plehm S; Unland R; Dirksen U; Borkhardt A; Staege MS; Müller-Tidow C; Richter GH
    Cell Cycle; 2009 Jul; 8(13):1991-6. PubMed ID: 19502792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation.
    Mu W; Starmer J; Yee D; Magnuson T
    Epigenetics Chromatin; 2018 Dec; 11(1):71. PubMed ID: 30522506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of a constitutively active prolactin receptor causes histone trimethylation of the p53 gene in breast cancer.
    Tan D; Tang P; Huang J; Zhang J; Zhou W; Walker AM
    Chin Med J (Engl); 2014; 127(6):1077-83. PubMed ID: 24622438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The polycomb group protein EZH2 inhibits lung cancer cell growth by repressing the transcription factor Nrf2.
    Li Z; Xu L; Tang N; Xu Y; Ye X; Shen S; Niu X; Lu S; Chen Z
    FEBS Lett; 2014 Aug; 588(17):3000-7. PubMed ID: 24928441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
    Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
    J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EZH2 promotes the expression of LPA1 by mediating microRNA-139 promoter methylation to accelerate the development of ovarian cancer.
    Wu D; Wu F; Li B; Huang W; Wang D
    Cancer Cell Int; 2020 Nov; 20(1):551. PubMed ID: 33292225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.